Clinical Research Directory

Inclusion Criteria: * Radiography inclusion criteria 1. angiographically confirmed de novo coronary artery lesion; 2. target lesion stenosis must be ≥70% or ≥50% with clear evidence of myocardial ischaemia (visual assessment); 3. target lesion vessel diameter is between 2.75mm and 4.0mm, target lesion length must be ≤25mm (visual assessment); 4. either one or two target lesions to be treated; if two target lesions, they must be located in different target vessels; 5. successful target lesion preparation: residual stenosis ≤30%, no flow-restricting entrapment, and TIMI grade 3 flow; General inclusion criteria <!-- --> 1. subjects at the age between ≥18 and ≤80 years old; 2. patients with symptoms or evidence of myocardial ischaemia; 3. subjects are willing to participate in the study, sign informed consent form, and accept clinical follow-up after operation and at 30 days, 6 months, 9 months and 12 months after operation. Exclusion Criteria: * Radiography exclusion criteria 1. in-stent lesions; 2. For the left main disease, true bifurcation lesion, chronic total occlusive lesions; 3. Severely calcified lesions and tortuous lesions; lesions that have failed pretreatment; lesions unsuitable for balloon delivery and dilatation; 4. Previous use of any brand of drug-coated balloon in the target vessel. General inclusion criteria <!-- --> 1. Any patient with myocardial infarction within one month; 2. Patients with severe congestive heart failure (NYHA Level IV severe heart failure) or severe valvular heart disease; or left ventricular ejection fraction of less than 35%; 3. Patients with stroke, peptic ulcer or gastrointestinal bleeding within the past 6 months; or patients with bleeding tendency or coagulation disorders; 4. Patients with severe liver failure (ALT and AST are larger than 3 times of the upper limit of normal value), who are judged to be not applicable to angiography by investigators; 5. Patients with severe renal failure(eGFR\<30ml/minute) or such medical history, failure to comply with angiography conditions; 6. Subjects who are intolerance or allergic to heparin, contrast agent, Biolimus, polyethylene oxide and polylactic acid - glycolic acid polymer; 7. Patients who plans to accept selective operation within 1 year; 8. Patients who are participating in the clinical trial of other drug or device without reaching the time limit of primary endpoint; 9. Subjects who are considered to be not applicable to be enrolled by investigators due to other reasons.